Equally important, the recent data suggest the α3/α5/β4 subunit cluster may harbor a promising and much needed new target for the development of next generation, nonclassical pharmacotherapeutics designed to treat not only nicotine addictions but also lung cancer, which may involve the dysregulation of epithelial and other α3/α5/β4-expressing cells.
